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2216Objective: We compared the histologic findings in explanted CorMatrix (9 patients) and autologous
pericardium (9 patients) used for valvuloplasty of the aortic (7 patients) and/or mitral (11 patients) valve in
patients with congenital heart defects.
Methods: We used standard tissue stains and immunohistochemistry to identify the inflammatory cell type.
Results: CorMatrix was associated with an intense inflammatory response in the surrounding native tissue,
extending into CorMatrix in 8 of 9 cases, continuing to the longest follow-up point (9 months). The typical
response included macrophages and giant cells in contact with the material, surrounded by lymphocytes,
macrophages, plasma cells, and eosinophils. The thickness of the residual CorMatrix material was 280 to
300 mm, similar to the nominal thickness at implantation and unrelated to the implantation duration. Only at
the longest follow-up interval was any significant resorption of CorMatrix material evident. A neointima had
formed on the surface of CorMatrix, increasing in thickness with the period in situ. Mild cellular infiltration
of CorMatrix was noted in all cases; however, in no case, did it appear that CorMatrix was being remodeled
into tissue resembling a 3-layered native valve. In contrast, a near absence of any inflammatory reaction was
seen and no eosinophilia associated with autologous pericardium was present, irrespective of the duration in
situ. Furthermore, we observed more tissue infiltration, remodeling, vascularization, and neointima formation
with autologous pericardium.
Conclusions: Although CorMatrix used for valve repair induced an intense inflammatory response, little or
no remodeling to form tissue resembling a 3-layered native valve was seen at 9 months after implantation.
(J Thorac Cardiovasc Surg 2014;148:2216-25)See related commentary on pages 2225-6.Supplemental material is available online.According to The Society of Thoracic Surgeons database,
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The Journal of Thoracic and Cardiovascular SurOften these corrective operations involve the use of a tissue
substitute to reconstruct abnormal or missing valve struc-
tures. The ideal material would be compatible with growth,
pliable, resistant to tearing, calcification, and shrinkage, and
heal without scar formation. A number of materials have
been used as a tissue substitute, including autologous peri-
cardium (with or without glutaraldehyde fixation), pre-
served xenopericardium, and various prosthetic materials
(eg, polyethylene terepthalate [Dacron, DuPont, Wilming-
ton, Del] and polytetrafluoroethylene [Gore-Tex, W. L.
Gore & Associates, Inc, Flagstaff, Ariz]). However, these
materials can cause an inflammatory response, cicatrization,
aneurysm formation, and calcification.2-4 Nonresorbable
materials will not change size or shape over time; thus,
additional procedures could be required to accommodate
the growth of the patient. Although evidence has shown
that glutaraldehyde-fixed autologous pericardium used for
valve leaflet extension provides greater resistance to retrac-
tion and degeneration than bovine pericardium, a major
concern has been the lack of growth potential.5,6
Decellularized extracellular matrix from porcine small in-
testinal submucosa has been developed and commercialized
(CorMatrix Cardiovascular, Inc, Alpharetta, Ga) as agery c November 2014
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maintain a 3-dimensional architecture essential for ingrowth
of native cells7,8 and to provide molecular signals
that influence proliferation, differentiation, and cell
metabolism.9 The results of testing of CorMatrix in various
animal models have suggested that after induction of
ingrowth of autologous cells, the material will be resorbed,
allowing regeneration of local tissue.10 Although the animal
results have been promising, few long-term follow-up data
are available on the use of this material in patients with
congenital heart defects.11-13 Preliminary data have
indicated the feasibility of the use of CorMatrix for
congenital heart disease surgery. However, these studies
have had several limitations, including a small sample size,
no long-term follow-up data, and few histologic descriptions
of the explanted material.
In the present study, we compared the histologic findings
in explanted CorMatrix and autologous pericardium that
had been used for valvuloplasty of the aortic and/or mitral
valve in patients with congenital heart defects.CMETHODS
Subjects
The patients were identified by a search of the cardiac surgery and
pathology databases at Boston Children’s Hospital for all patients
in whom CorMatrix or autologous pericardium had been used for
valvuloplasty of the mitral or aortic valve and who had undergone surgery
on the valve from February 2006 to February 2013. The inclusion criteria
were (1) a congenital anomaly of the aortic, mitral, or common
atrioventricular valve, (2) surgical valvuloplasty with the use of CorMatrix
or autologous pericardium, (3) survival for 5 days after surgery,
(4) explantation of the tissue substitute at a subsequent operation or at
autopsy. The patients were excluded if a history of infective endocarditis
involving the target valve was present.Clinical Data
The data were retrospectively collected from a detailed review of the
medical records, echocardiographic and catheterization reports, operative
notes, and pathology reports. The demographic data included age at
surgery and gender. The clinical data included cardiac diagnoses, number
of procedures (surgical and interventional) performed on the valve before
implantation of the tissue substitute, and valve function (Doppler and/or
catheterization valve gradient and regurgitation severity). The surgical
data included the manner in which the tissue substitute was used for
valve reconstruction (patch completely surrounded by native tissue or
leaflet extender with free edge not in contact with native tissue) and the
duration that the tissue substitute remained in situ from implantation to
explantation.Surgery
Autologous pericardium was harvested at surgery, fixed in 0.625%
glutaraldehyde for 2 to 10 minutes, and rinsed in physiologic saline.
CorMatrix was rehydrated in physiologic saline for 10 minutes in
accordance with the package instructions. The tissue substitute was cut
to the appropriate size and shape and sewn into place with 7-0 Prolene
suture. A variety of implantation techniques were used for aortic valve
repair, including leaflet edge augmentation, enlargement of the belly ofThe Journal of Thoracic and Carthe leaflet, or complete leaflet replacement. Mitral valve repair mainly
involved augmentation of the ‘‘belly’’ of the valve leaflet, with
maintenance of the edge support structures.Histologic Examination
Valve tissue explanted at surgery or available from autopsy was fixed in
10% neutral-buffered formalin, embedded in paraffin, and cut into 5-mm
sections. The sections were mounted and stained with hematoxylin and
eosin, Masson’s trichrome, and Miller’s elastic stain. Inflammation was
graded semiquantitatively (none, minimal, mild, moderate, and severe)
by an experienced cardiac pathologist (R.F.P.) according to the density
and type of inflammatory cells present. The eosinophil response was
quantified by counting the number of cells per high power field using a
calibrated grid. Semiquantitative grading (none, minimal, mild, moderate,
and severe) was also used to assess the degree of cell and tissue infiltration
into the material, neovascularization of the surrounding tissue, neointimal
formation on the material, and calcification of the material. The thickness
of residual CorMatrix was measured in sections presenting a cross-section
of the material using a calibrated stage.
Immunohistochemistry or in situ hybridization was performed on
paraffin-embedded sections of explanted CorMatrix and the surrounding
tissue, which had been prepared using standard methods. CD68 was used
as a general marker for macrophages, CD163 for M2 macrophages,
CD3, CD4, and CD8 for T lymphocytes, CD20 for B lymphocytes, and
CD79a for plasma cells. Staining for macrophages was performed in
5 cases. Analysis of the T and B lymphocytes and plasma cells was
performed in 2 cases. In situ hybridization was performed for kappa
and lambda light chain mRNA expressed in the plasma cells in 2 cases.
Immunohistochemistry was not performed on explanted autologous
pericardium because of the paucity of inflammatory cells.Statistical Analysis
Continuous data are summarized as the median and range and
categorical data as the frequency and percentages. Comparisons of
demographic, preoperative, and surgical characteristics between the groups
were performed using the Wilcoxon rank sum test for continuous variables
and Fisher’s exact test for categorical variables. Analyses were performed
using Stata, version 12.1 (StataCorp, College Station, Tex).
The present study was conducted in accordance with the guidelines
from the Committee on Clinical Investigation and the hospital
institutional review board approved the protocol (IRB-P00003183 and
IRB-P00002929).RESULTS
Subjects
During the study period, 60 patients were identified
who had undergone mitral or aortic valvuloplasty using
CorMatrix or autologous pericardium. Of these patients, 3
were excluded because of infective endocarditis, leaving
57 patients (Table 1). Of the 57 patients, 25 had undergone
mitral valvuloplasty only, 27 aortic valvuloplasty only, and
5 both mitral and aortic valvuloplasty. CorMatrix was used
for repair of the mitral valve in 17 patients and autologous
pericardium in 16 patients. Autologous pericardium used at
the initial valvuloplasty was replaced by CorMatrix in
2 patients, and CorMatrix was replaced by autologous
pericardium in 1 patient. CorMatrix was used for aortic
valve repair in 26 patients and autologous pericardium in
12 patients. Three patients underwent replacement ofdiovascular Surgery c Volume 148, Number 5 2217
TABLE 1. Demographic, preoperative characteristics, and surgical information
Variable
Mitral valve Aortic valve
CorMatrix Autologous pericardium P value CorMatrix Autologous pericardium P value
Patients 17 16 26 12
Age (y) .27 .11
Median 2.2 1.3 8.7 2.9
Range 0.1-26.9 0.1-22.5 0.2-25.4 0.1-16.2
Gender
Male 9 8 16 8
Female 8 8 10 4
Previous procedures .14 .92
Median 2 1 1 1
Range 0-5 0-3 0-7 0-2
Preoperative valve function
Moderate regurgitation or more 13 9 17 7
Moderate stenosis or more 4 7 9 5
Surgical use .27 .48
Patch 10 (59) 5 (20) 11 (42) 3 (25)
Free edge 6 (35) 8 (80) 13 (50) 7 (58)
Both 1 (6) 0 (0) 2 (8) 2 (17)
Data presented as n (%) or median and range.
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CorMatrix. Both autologous pericardium and CorMatrix
were implanted concomitantly in 2 patients and at
sequential operations in 1 patient.
Of the patients who had undergone mitral valvuloplasty,
8 (47%) of 17 in whom CorMatrix was used and 6 (38%) of
16 in whom autologous pericardium was used underwent
explantation of the tissue substitute at valve replacement
(11 patients) or subsequent valvuloplasty (3 patients)
for valve dysfunction (Tables 2 and 3). The patients
undergoing explantation of either CorMatrix orTABLE 2. Comparison of demographics, preoperative characteristics, and
Variable
Mitral valve
CorMatrix explanted CorMatrix in s
Explantations 8 9
Age (y)
Median 1.5 4.7
Range 0.1-14.5 0.8-26.9
Gender
Male 3 6
Female 5 3
Previous procedures
Median 2 2
Range 0-5 0-3
Preoperative valve function
Moderate regurgitation or more 6 7
Moderate stenosis or more 2 2
Surgical use
Patch 7 (88) 3 (33)
Free edge 1 (12) 5 (56)
Both 0 (0) 1 (11)
Data presented as median and range or n (%).
2218 The Journal of Thoracic and Cardiovascular Surpericardium after mitral valvuloplasty did not differ
significantly from those with the material remaining in
situ in age, gender, number of previous valve procedures
or type of repair (Table 2). The median length of time in
situ was 64 days (range, 5-261) for the explanted CorMatrix
and 1010 days (range, 14 to 1506) for the explanted
autologous pericardium.
Of the patients who underwent aortic valvuloplasty, 3
(12%) of 26 in whom CorMatrix and 8 (67%) of 12 in
whom autologous pericardium was used underwent
explantation of the tissue substitute at valve replacementsurgical information stratified by presence of CorMatrix
Aortic valve
itu P value CorMatrix explanted CorMatrix in situ P value
3 23
.31 .75
6.0 8.7
4.7-11.8 0.2-25.4
3 13
0 10
.49 .05
4 1
0-7 0-2
1 16
2 7
.08 .18
3 (100) 8 (35)
0 (0) 13 (57)
0 (0) 2 (9)
gery c November 2014
TABLE 3. Comparison of demographics, preoperative characteristics, and surgical information stratified by presence of autologous pericardium
Variable
Mitral valve Aortic valve
Autologous
pericardium
explanted
Autologous
pericardium
in situ P value
Autogolous
pericardium
explanted
Autogolous
pericardium
in situ P value
Explantations 6 10 8 4
Age (y) .66 .93
Median 1.4 1.3 2.9 5.8
Range 0.5-11.1 0.1-22.5 0.1-16.2 0.1-14.2
Gender
Male 3 5 5 3
Female 3 5 3 1
Previous procedures .73 .37
Median 1 1 1 2
Range 0-3 0-2 0-2 0-2
Preoperative valve function
Moderate regurgitation or more 2 7 6 1
Moderate stenosis or more 4 3 2 3
Surgical use .60 .75
Patch 2 (33) 2 (20) 2 (25) 1 (25)
Free edge 4 (67) 8 (80) 4 (50) 3 (75)
Both 0 (0) 0 (0) 2 (25) 0 (0)
Data presented as median and range or n (%).
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valvuloplasty for valve dysfunction (4 patients), or at
autopsy (1 patient). Patients undergoing explantation of
the tissue substitute did not differ significantly from those
with the material in situ in age, gender, and type of use
for the tissue substitute (Table 3). However, patients
undergoing explantation of CorMatrix had undergone
significantly more procedures (P¼ .05) on the valve before
implantation of the CorMatrix than did those in whom the
CorMatrix remained in situ. This was not the case for autol-
ogous pericardium. The median period in situ was 63 days
(range, 49 to 198) for the explanted CorMatrix and 1747
days (range, 6 to 6047) for the explanted autologous
pericardium.Histologic Examination
Explanted CorMatrix material was available for
examination from the mitral valve in 6 patients and the
aortic valve in 3 patients (Table 4). Explanted autologous
pericardium from the mitral valve was available in 5
patients and the aortic valve in 4 patients (Table 4). The
histologic findings are reported together for the aortic and
mitral valves because of the small number of samples and
the similarity of the findings between the 2 groups.
Residual CorMatrix was apparent in all 9 cases as
a continuous, layered, loose-appearing, intensely eosino-
philic material (Figure 1). Suture holes were often evident
in the CorMatrix and in surrounding native tissue,
indicating the location of the boundary between the native
tissue and tissue substitute. An intense inflammatoryThe Journal of Thoracic and Carresponse, graded as either moderate or severe in 8 of the 9
cases, was seen in the surrounding native tissue and
extending into the CorMatrix (Figure 2). The typical
response includedmacrophages (often palisading) and giant
cells in contact with the material (Figure E1), surrounded by
a mixed inflammatory infiltrate consisting of lymphocytes,
macrophages, plasma cells, and eosinophils. Immunostain-
ing showed abundant CD68-positive macrophages, most of
which also stained positively for CD163, a marker for
M2-type macrophages. Both CD4- and CD8-positive
T cells, CD20-positive B cells, and numerous
CD79a-positive plasma cells were present. In situ
hybridization revealed that the plasma cell population was
a mixture of lambda- and kappa-producing cells, indicating
a polyclonal response typical of a reactive process. The
severity of the inflammatory response was unrelated to the
duration of implantation. A prominent eosinophilic
component to the infiltrate was present in all the moderate
and severe cases (Figure 3). The mean number of
eosinophils per high power field was 71  67 (range,
2-211) for all 9 cases, with the numbers unrelated to the
duration of implantation. The thickness of the residual
CorMatrix material ranged from 280 to 300 mm, similar
to the nominal thickness of the material at implantation,
and was not related to the duration of implantation at
261 days. Only in the material with the longest duration
in situ was any significant breakdown of the CorMatrix
material evident. Trivial to mild microscopic calcification
was seen in 4 of the 9 CorMatrix explants. A neointima,
usually with evidence of neovascularization, had formed
on the surface of the CorMatrix material (Figure 4), withdiovascular Surgery c Volume 148, Number 5 2219
TABLE 4. Histologic findings in explanted valves after valvuloplasty using CorMatrix or autologous pericardium
Pt.
No. Valve Age Diagnosis
Previous
interven-
tions (n) Use*
In
situ (d)
Reason
explanted Inflam Eos
Residual
CMy
(mm) Infiltr Neovasc Neointima Calc
CM
1 MV 2 mo Shones complex
(MS, AS)
1 Posterior leaflet
augmentation
261 Fixed posterior
leaflet
4 17 280 1 2 2 1
2 MV 11 mo Shones complex 5 Posterior leaflet
augmentation
27 Fixed posterior
leaflet, tethering
4 92 300 2 1 1 0
3 MV 4 mo Rt dom CAVC
after repair
2 Lateral leaflet
augmentation
18 Residual
regurgitation
3 28 290 1 0 1 0
4 MV 14.7 y Rt dom CAVC
after repair
3 Inferior leaflet
augmentation
7 Residual
regurgitation
z z z z z z z
5x MV 2 y CAVC after repair
cleft open
4 Anterior, lateral
leaflet
augmentation
101 CM dehiscence
regurgitation
4 116 280 2 1 2 2
6 MV 1.6 y CAVC after repair 1 Superior leaflet
augmentation
223 MV stenosis,
immobile
anterior leaflet
4 43 300 1 2 3 0
7 MV 3.4 y Borderline HLHS,
AS, MS,
hypoplastic arch
1 Repair perforated
posterior leaflet
114 Marked thickening
of leaflets
4 103 300 1 3 3 1
8 MV 9.3 y CAVC after repair
cleft open
1 Patch closure of
cleft
5 Patch folded on
itself
jj jj jj jj jj jj jj
9 AoV 4.7 y Borderline HLHS
(AS, MS)
4 Creation of NC
leaflet
198 AR{ 4 211 280 1 2 2 2
10 AoV 7.6 y HLHS AS, MS 7 Augmentation of
3 leaflet edges
49 Death on LVAD
awaiting
transplant,
autopsy
3 23 280 2 1 1 0
11 AoV 12 y Severe AR, BAV
aortic root
dilation,
Ehler-Danlos
0 RC leaflet
augmentation
63 Residual AR, RC
leaflet prolapse,
retracted leaflets
2 2 300 1 0 1 0
AP
1 MV 3.6 y Shones complex,
supra mitral
ring, parachute
MV, BAV,
coarctation
1 Posterior leaflet
augmentation
940 MS, rigid posterior
leaflet
0 0 1 1 4 2
2 MV 11 y Rt dom CAVC
after repair
2 Inferior leaflet
augmentation
1274 MS jj jj jj jj jj jj
3 MV 1 y Shones complex
MS, AS,
coarctation
after repair
0 Posterior leaflet
augmentation
14 Residual MS 0 0 0 0 1 0
4 MV 6 mo AS, MS, mild
LV hypoplasia,
EFE
0 Anterior leaflet
augmentation
1079 Residual MS after
2-ventricle
conversion
1 2 2 2 3 2
5 MV 9 mo Transitional CAVC
after repair
1 Inferior leaflet
augmentation
163 MS, MR thickened
leaflets
0 0 2 2 3 0
6 MV 10.8 y HLHS (MS/AS) 3 Posterior leaflet
augmentation
1506 Residual MS/MR 0 0 3 3 3 0
7 AoV 19 d Borderline HLHS
MS, AS
1 Replacement
of NC leaflet
1701 Recurrent AR,
immobile
NC leaflet
jj jj jj jj jj jj
8 AoV 9 mo Critical AS 2 Replacement
of RC leaflet
1077 Thickened,
immobile
RC leaflet
0 0 2 2 3 0
(Continued)
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TABLE 4. Continued
Pt.
No. Valve Age Diagnosis
Previous
interven-
tions (n) Use*
In
situ (d)
Reason
explanted Inflam Eos
Residual
CMy
(mm) Infiltr Neovasc Neointima Calc
9 AoV 4.4 y AS, AR, BAV 1 Replacement
of RC leaflet
2310 AR, retracted
RC leaflet
0 0 2 1 3 0
10 AoV 9 mo D-TGA, VSD,
cleft MV,
subvalvar PS
0 Anterior leaflet
augmentation
1868 Progressive
AR
jj jj jj jj jj jj
11 AoV 16.3 y BAV 0 Leaflet
replacement
1794 Asc Ao rupture,
severe AR
jj jj jj jj jj jj
12 AoV 4 mo BAV, AS 1 Augmentation
of right
noncoronary
cusp
6047 Progressive AR 0 0 2 2 2 2
13 AoV 16.7 y Unicommissural
AoV, AS
1 Right coronary
leaflet
6 Rapidly
progressive AR
jj jj jj jj jj jj
14# AoV 6 y VSD, dysplastic
AoV, pulmonary
valve, cleft MV
0 Noncoronary
leaflet
623 Progressive AR 0 0 3 3 3 0
Grading of the parameters was as follows: 0, none; 1, minimal; 2, mild; 3, moderate; 4, severe. Pt. No., Patient number; Inflamm, qualitative estimate of severity of inflammation
(R.F.P.); Eos, average number of eosinophils per field; CM, CorMatrix; Infiltr, extent of infiltration of the tissue substitute by native cells; Neovasc, qualitative estimate of the
density of new vessels at the edge of the tissue substitute; Neointima, qualitative estimate of the extent of neointima formation over the tissue substitute; Calc, qualitative estimate
of the amount of calcification of the tissue substitute; MV, mitral valve;MS, mitral stenosis; AS, aortic stenosis; Rt dom, right dominant; CAVC, common atrioventricular canal;
AoV, aortic valve; HLHS, hypoplastic left heart syndrome; NC, noncoronary; AR, aortic regurgitation; BAV, bicommissural aortic valve; LVAD, left ventricular assist device;
RC, right coronary; MR, mitral regurgitation; LV, left ventricular; EFE, endocardial fibroelastosis; D-TGA, D-transposition of the great arteries; VSD, ventricular septal defect;
PS, pulmonary stenosis; Asc, ascending; Ao, aorta. *Whether the tissue substitute was used as a patch surrounded by native tissue or as a leaflet extender with a free edge not in
contact with native tissue. yThickness of residual CMmaterial measured in samples sectioned on edge. zCM not present in the resected section sent to pathology. xReoperation at
85 days for dehiscence of CM patch on anterior leaflet. jjHistologic examination not requested on resected material or leaflet tissue not identified in the sample sent for histologic
examination. {Regurgitation resulted from native leaflets; CM leaflet was mobile and functioning. #Reoperation (AoV valvuloplasty without resection of autologous
pericardium) before explantation.
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situ. In some cases, it appeared that the CorMatrix was
being encased by a fibrous peel of neointima. Although
all cases showed a minimal or mild degree of cellular or
tissue infiltration of the CorMatrix material, in no caseFIGURE 1. Mediumpower photomicrographs ofCorMatrixmaterial at 18
days (patient 3) showing the layered connective tissue matrix, which was
eosinophilic on hematoxylin and eosin staining. The nuclei seen on the bot-
tom of the hematoxylin and eosin imagewere host inflammatory cells rather
than cells indigenous to the CorMatrix. Original magnification3100.
The Journal of Thoracic and Cardid it appear that CorMatrix was remodeling into tissue
resembling a 3-layered native valve.
The histologic reaction to autologous pericardium
(Figure E2) was much different than that to CorMatrix. A
near absence of any inflammatory reaction was found, and
no eosinophilia was found, irrespective of the duration in
situ. A greater degree of tissue infiltration, vascularization,
and neointima formation was present, at least in part
attributable to the longer implantation time. We did not
measure the thickness of pericardium, in part because it
was less well defined than the CorMatrix and in part
because no data were available about the thickness of the
original implant. Calcification was present in 3 of the
9 cases, usually localized to the areas around the sutures.
Immunostaining was not performed on explanted
autologous pericardium because of the paucity or absence
of inflammatory cells.
DISCUSSION
We did not identify important demographic or clinical
differences between the groups that had undergone
explantation of the tissue substitute and those with the
material remaining in situ, except that patients in whom
CorMatrix was explanted from the aortic valve had under-
gone more procedures on the valve before implantation of
the tissue substitute.diovascular Surgery c Volume 148, Number 5 2221
FIGURE 2. A, Low power photomicrograph of the inflammatory response to the CorMatrix material at 114 days (patient 7). Hematoxylin and eosin stain,
original magnification340. B, Medium power photomicrograph of the inflammatory response to the CorMatrix material at 198 days (patient 8). A mixed
infiltrate of lymphocytes, macrophages, plasma cells, and eosinophils were present. Hematoxylin and eosin stain, original magnification 3100.
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markedly. The CorMatrix material remained intact, with
little change in appearance throughout the follow-up period.
Only in the longest surviving explant was reabsorption of
the material evident. CorMatrix was associated with an
intense inflammatory response that had not abated at
9 months and included a striking number of eosinophils
and giant cells. We saw little evidence of remodeling or
reabsorption of the material and no appearance of tissue
resembling the native valve. In many cases, a thick
neointima had formed, suggesting the CorMatrix was being
encased. However, the explanted CorMatrix analyzed
histologically was only from about one half of patients in
whom it had been used for mitral valve repair and 12%
for aortic valve repair. It is possible that CorMatrix
remaining in situ would have a different appearance.
In contrast, autologous pericardium was not associated
with a significant inflammatory response. One possible
explanation could be that the pericardial samples were in
situ for much longer than was the CorMatrix, when the
inflammatory response would be expected to have abated.
However, even in the shorter duration pericardial cases
(eg, 14 and 163 days), no inflammation was found, although
a brisk inflammatory response at this interval was still
present in the CorMatrix samples. The pericardium became
less prominent with time, undergoing patchy resorption andFIGURE 3. High power photomicrographs of the eosinophilic infiltrate arou
(patient 8). Hematoxylin and eosin stain, original magnification 3200.
2222 The Journal of Thoracic and Cardiovascular Surremodeling. However, the pericardium was associated with
areas of calcification, usually around the surgical suture
sites.
USE OF CORMATRIX IN CONGENITAL HEART
DISEASE
Few reports have been published of the use of CorMatrix
in the repair of congenital heart defects.11-13 Most often it
has been used for reconstruction of the pericardium,
repair of vascular stenosis, or closure of intracardiac
defects. Very few reports have been published of heart
valve reconstruction or creation of a pulmonary monocusp
valve using CorMatrix. Scholl and colleagues11 reported
augmentation of 2 valves and creation of 4 pulmonary
monocusp valves using CorMatrix. Of the 4 monocusp
valves, 2 developed moderate or severe regurgitation within
the first year, but none became stenotic. A tricuspid valve
was explanted 4 months after valvuloplasty using
CorMatrix because of disruption of the valve during an
interventional catheter procedure. The histologic examina-
tion was reported to show inflammation, nearly complete
resorption of the CorMatrix with replacement by organized
collagen, and a luminal surface resembling endothelium.
Quarti and colleagues12 reported the short-term results
of valvuloplasty using CorMatrix in 9 patients (5 aortic,
2 tricuspid, 1 mitral, and 1 pulmonary monocusp) with and the CorMatrix material at (A) 27 days (patient 2) and (B) 198 days
gery c November 2014
FIGURE 4. Medium power photomicrograph of the neointimal (NI) layer
consisting of fibrous tissue with mild chronic inflammation and occasional
blood vessels around the CorMatrix (CM) material at 223 days (patient 6).
Also, note themacrophages and foreign body giant cells at thematerial–tissue
interface. Hematoxylin and eosin stain, original magnification3100.
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gone reoperation, and valve function was reported to be
excellent in all.
Witt and colleagues13 reported the creation of 3
pulmonary monocusp valves. One patient with complex
disease died acutely. After almost 2 years, 1 had severe
insufficiency and the other mild-to-moderate insufficiency.
These investigators reported the histologic findings in 2
other cases.13 In the first case, CorMatrix was used in a
patient with tetralogy of Fallot to patch the right ventricular
outflow, which then became severely obstructed 1.5 years
after surgery. The explanted material was reported to
show dense fibrosis and chronic inflammation. In the second
case, a CorMatrix patch used to close an atrial septal defect
was biopsied during reoperation unrelated to the CorMatrix
material. Microscopic examination was reported to show
diffuse myxoid degeneration of the patch material with
chronic inflammation, including numerous eosinophils.
ANIMAL STUDIES
Matheny and colleagues14 replaced a single pulmonary
leaflet with CorMatrix in 4 normal pigs and examined the
implants 56 to 111 days later. Valve function was reported
to be normal by echocardiography immediately after
implantation and at explantation in all 4 animals. The
investigators reported that the CorMatrix was remodeled
progressively from the base of the leaflet to the free edge,
yielding a structure that resembled the adjacent native
leaflets by 111 days.14 The inflammatory response was
only described at 56 days and was composed mostly of
macrophages, with fewer neutrophils.
Studies in dogs and pigs,15,16 in which defects created
in the anterior right ventricular wall were filled withThe Journal of Thoracic and Carextracellular matrix material derived from either small
intestine submucosa or urinary bladder submucosa, have
shown ingrowth of cardiac myocytes, fibrous, and adipose
tissue and blood vessels. The reconstituted wall has been
reported to contract spontaneously and in response to
stimulation, developing 70% of the normal contractile
force. The inflammatory response was not described in
these studies, which had focused on myocyte regeneration
and functional assessment.
Material fashioned from pig small intestine or
bladder submucosa has been used as a tissue substitute in
other settings, including urinary bladder reconstruction,
abdominal wall replacement, hernia repair, tendon repair,
and others.17-19
In all these animal models, the tissue substitute was
resorbed and replaced with native tissue within 12 to 15
weeks. The remodeling process involved an immune
response with neutrophils and eosinophils early (peaking
at 7-10 days) and switching to a predominantly macrophage
cell type at around 28 days.20
COMPARISON OF OUR FINDINGS WITH
PUBLISHED RESULTS
The histologic findings in 3 previously reported human
cases11,13 were generally in agreement with our findings
regarding the presence of chronic inflammation and
eosinophilia, except that the severity seemed greater in
our series. However, the CorMatrix material had largely
been resorbed in all 3 reported cases, in contrast to our
finding of virtually intact material in all our cases. A
longer follow-up period of 12 to 18 months, compared
with our longest follow-up period of nearly 9 months, is
the likely explanation in 2 of the cases. However, the
third case was evaluated only 4 months after tricuspid
valvuloplasty but was reported to show only small islands
of residual CorMatrix.
In contrast, our findings differed markedly from those
reported in animal testing of CorMatrix and similar
materials. Unlike the report of pulmonary valve leaflet
replacement in pigs, we saw almost no resorption of the
CorMatrix material used for either aortic or mitral
valvuloplasty, even at durations in situ more than twice
the longest reported by Matheny and colleagues14 (261 vs
111 days). Nor did we observe development of tissue
resembling the native valve. Instead, we saw a chronic,
mixed cellular inflammatory response at the junction of
the CorMatrix material with native tissue that was constant
from soon after implantation to the longest follow-up point.
The part of the CorMatrix not in contact with the native
tissue remained essentially acellular and showed little or
no evidence of remodeling.
The differences between our findings in human subjects
and those in pigs could be related to several factors. First,
CorMatrix is allogeneic in pigs but xenogeneic in humans.diovascular Surgery c Volume 148, Number 5 2223
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tory response that would be less conducive to positive
remodeling of the tissue substitute. For example, pigs
express the gal epitope and humans do not.21 Preformed
antibodies to the gal epitope in humans seem to be a primary
cause of acute rejection of organs in xenotransplantation.22
Perhaps an inflammatory response to this or other antigens
was responsible for the divergent findings. The inflamma-
tory process was protracted, and remodeling of a
submucosa-derived tissue substitute was delayed in a
transgenic mouse model that does not express the gal
epitope.23 Furthermore, the variable anti-gal titers and
activity among humans24,25 could explain, at least in part,
why some recipients appear, clinically, to do well and
others must undergo reoperation for valve dysfunction.
Second, in the pig model, a large portion of the leaflet
was in contact with the native tissue. Our observations
and those of others have indicated that cellular invasion
and remodeling of the tissue substitute only occur at the
edge in contact with native tissue and not at the free edge
in contact with the blood stream. Much more of the
circumference of the tissue substitute leaflet was in
contact with the native tissue in the pig model compared
with the small pieces of material used as leaflet extenders
in our aortic valve patients. This was not true for material
used as a patch that would be surrounded by native tissue.
Finally, the pulmonary valve in the pig model was a
normal valve, in contrast to the very abnormal valves in
our patients. Perhaps the molecular cues present in
normal valve tissue, but absent from congenitally
abnormal valves, would promote remodeling of
CorMatrix to relatively normal native tissue in the pig
model.
Study Limitations
Our study had several important limitations. First, this
was a small sample of patients reviewed retrospectively in
whom CorMatrix had been used for valve repair. Second,
the number of explants available for histologic study was
even smaller, limiting our ability to draw conclusions about
the overall group in which CorMatrix had been used.
Finally, the length of follow-up for the CorMatrix was short;
thus, we might have missed favorable remodeling that
occurred late after implantation.
CONCLUSIONS
Unlike autologous pericardium, CorMatrix was associ-
ated with an intense, chronic inflammatory response
containing eosinophils and giant cells at its junction with
native tissue that had not abated even after 9 months in
situ. Minimal remodeling of the CorMatrix was found at 9
months after implantation in the small number of explants
examined, with most of the material remaining acellular
and no evidence of formation of tissue resembling the native2224 The Journal of Thoracic and Cardiovascular Survalve. We have no direct information about CorMatrix that
remains in situ in patients with a favorable clinical outcome.References
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DInnovation in both operative techniques and devices has
been a hallmark of thoracic surgery since its inception.
Included has been the search for the optimal prosthetic
patch, a quest that has been ongoing since the earliest years
of congenital heart repairs. A biologic scaffold that allows
recipient cellular ingrowth and remodeling with subsequent
appropriate native tissue function and growth potential
would be the ultimate solution to the patch dilemma.
When animal studies suggested that an extracellular matrix
made from the submucosa of porcine small intestine
(CorMatrix; CorMatrix Cardiovascular, Inc, Roswell, Ga)
provided a bioscaffold that allowed ingrowth of ‘‘organized
and healthy tissue,’’ optimism, perhaps out of proportion to
the evidence base, ensued. Written information provided by
the manufacturer1 further suggested that their acellular
biomaterial could be expected to regulate cell adhesion,
cell differentiation, cell division, and cell migration.
CorMatrix was initially recommended for pericardial
reconstruction and, again according to the company’s
brochure, ‘‘Clinical data suggest complete reformation of
the pericardial space, including an intact mesothelial
lining.’’ Interestingly, a recent publication, ‘‘Histology of
CorMatrix Bioscaffold 5 Years After Pericardial Closure,’’reported that with regard to the histologic analysis of the
explanted pericardial patch ‘‘no evidence was found of an
endothelial lining on the putative visceral face of the sam-
ple.’’2 This suggested that further investigation into the
behavior of CorMatrix, even when used in its most funda-
mental application, was warranted.
It seems fair to say that evidence showing that CorMatrix
remodels and restores function when used for cardiac valve
reconstruction is at best scanty and is based primarily on
animal studies (where in many cases the bioscaffold was
allogeneic) and clinical reports with relatively small
numbers of patients and short follow-up describing echo-
cardiographic findings of repaired valves.3 This reinforces
the importance of this article by Zaidi and colleagues4
from Boston Children’s Hospital, which gives us histologic
information on the status of cardiac valve patches explanted
after failed valve repairs.
The study has several weaknesses recognized by its
authors. The overall number of patients with CorMatrix
valve repairs was small, and the number of explants avail-
able for histologic study was even smaller (n ¼ 9). This
small sample was also divided between mitral (n ¼ 6) and
aortic (n¼ 3) reconstructions. The duration of implantation
was short in a number of patients, with only 5 of 9 patches in
situ longer than 3 months (101-261 days). The study thus
can’t address favorable remodeling that might be occurring
at a later point after implantation, because we have no data
on the status of the CorMatrix in patients with a more dura-
ble valve repair.
With that said, this is the largest experience with human
explants of CorMatrix used for valve repair, and the histo-
logic findings are consistent. There was an intense inflam-
matory response to the patches that did not abate as late
as 9 months. In some cases, this was associated with a
fibrous peel of neointima that appeared to be encasing the
CorMatrix. This mixed inflammatory infiltration is very
concerning and in keeping with histologic findings in previ-
ously reported human cases.5 Only in the material with thediovascular Surgery c Volume 148, Number 5 2225
FIGURE E1. A, Medium power photomicrograph of palisading histiocytes at the border between the CorMatrix (CM) material and host tissue at 63 days
(patient 10), with a moderate chronic inflammatory response in the surrounding host tissue. Hematoxylin and eosin stain, original magnification 3100.
B, High power photomicrograph of macrophages and foreign body giant cells at the CorMatrix (CM)–tissue interface. Hematoxylin and eosin stain, original
magnification 3200.
FIGURE E2. A and B, Low power photomicrographs of the host tissue response to autologous pericardium (AP) showing neointimal (NI) formation, with
an absence of inflammation in the surrounding host tissue at 940 days (patients 1). A, Hematoxylin and eosin stain and B, trichome stain; original
magnification 340 for both. C, Medium power photomicrograph showing an absence of inflammation adjacent to autologous pericardium (AP) at 163
days (patient 5). Hematoxylin and eosin stain, original magnification 3100.
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